DNA X

DNA X (SONM.US) opened sharply lower, with pre-market trading dropping from yesterday's close of $5.26 to as low as $4.604, a decline of over 12.5%, and the regular session opened at $4.710, down 10.5% from the prior close. The company announced a private placement of 1,346,531 Series B preferred shares at approximately $6.02 per share, raising $8.1 million, coupled with the earlier termination of the $500 million ChEF equity facility, which fueled concerns over further dilution and financing structure changes. The current price of $4.710 is 61.7% below the 52-week high of $12.30 but still up 63.5% year-to-date, and it sits below the 20-day MA of $4.908, signaling short-term technical weakness. While Q1 net profit surged to $6.34 million, up 1,284% YoY, operating income was -$3.618 million, leaving fundamental improvement in question.